Physician profile
Grace U Chung
NPI 1235111436
$9,072.99
in general payments reported to CMS, 2019-2025
36 companies · $1,407 in 2025
The $1,407 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,314 · 2020: $393 · 2021: $1,113 · 2022: $1,452 · 2023: $1,511 · 2024: $1,884 · 2025: $1,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,356 · Education: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,355.54 |
| Education | $445.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,297.10 | 2019-2025 | Skyrizi |
| Janssen Biotech, INC. | $1,127.63 | 2020-2025 | Tremfya, Simponi, Stelara |
| Lilly USA, LLC | $902.50 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $837.69 | 2019-2025 | Winlevi, Odomzo, Blu-U |
| Novartis Pharmaceuticals Corporation | $745.40 | 2019-2025 | |
| Incyte Corporation | $463.56 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $440.94 | 2019-2024 | Targretin, Arazlo, Cabtreo |
| Leo Pharma INC. | $435.90 | 2019-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $432.21 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $277.10 | 2019-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $210.51 | 2023-2025 | Sotyktu |
| Ucb, INC. | $201.44 | 2019-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $193.15 | 2023-2024 | Vtama |
| Amgen INC. | $165.85 | 2021-2025 | Otezla, Otezla |
| Pfizer INC. | $164.98 | 2019-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $138.36 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.48 | 2022-2025 | Spevigo |
| Genentech USA, INC. | $133.82 | 2019-2022 | |
| Genzyme Corporation | $110.76 | 2021-2024 | |
| Epi Health, LLC | $100.59 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| Biofrontera INC. | $64.72 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $62.94 | 2023 | |
| Celgene Corporation | $55.48 | 2019 | |
| Sandoz INC. | $48.09 | 2019-2020 | |
| Botanix Sb INC | $34.40 | 2025 | Sofdra |
| Journey Medical Corporation | $27.97 | 2019-2023 | |
| Dermira, INC. | $26.74 | 2019-2020 | |
| Krystal Biotech INC | $22.30 | 2023 | Vyjuvek |
| Kerecis Limited | $20.44 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Dusa Pharmaceuticals, INC. | $18.58 | 2019 | |
| Organon LLC | $17.15 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $17.00 | 2024 | Ycanth |
| Aclaris Therapeutics, INC. | $14.71 | 2019 | |
| Mylan Pharmaceuticals INC. | $14.32 | 2019 | |
| Strata Skin Sciences, INC. | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.